Bluebird bio

bluebird bio, Inc.

Company type	Public (formerly)
Industry	Biotechnology
Predecessor	Genetix Pharmaceuticals
Founded	April 1992 (1992-04) in Massachusetts, United States
Founder	Philippe Leboulch, Irving London
Headquarters	Somerville , United States
Area served	Global
Key people	Nick Leschly (CEO as of 2010)
Products	Betibeglogene autotemcel (Zynteglo), Elivaldogene autotemcel (Skysona), Lyfgenia
Owner	Investment funds managed by The Carlyle Group and SK Capital Partners
Number of employees	(reduced by 25-30% between 2022 and 2024; exact number not specified)

bluebird bio, Inc., based in Somerville, Massachusetts, operates as a biotechnology firm dedicated to developing gene therapies for serious genetic disorders. The company is under the ownership of investment groups managed by The Carlyle Group and SK Capital Partners, with a focus on pioneering treatments for uncommon diseases.

Its flagship therapy, betibeglogene autotemcel (marketed as Zynteglo), is designed to treat transfusion-dependent beta thalassemia (TDT) and has received approval from the European Medicines Agency. Although it represents a significant medical advancement, the therapy’s $1.8 million cost has generated considerable discussion within the industry due to its position among the highest-priced treatments worldwide.

bluebird bio is progressing with its LentiGlobin gene therapy aimed at treating sickle cell disease and cerebral adrenoleukodystrophy. The company also develops T cell-based treatments targeting various cancers such as acute myeloid leukemia, Merkel-cell carcinoma, diffuse large B-cell lymphoma, and MAGEA4 solid tumors. This diverse portfolio reflects bluebird bio’s strategy to broaden its presence in rare genetic disorders and oncology markets.

History

The organization was originally established as Genetix Pharmaceuticals in April 1992 by MIT professors Philippe Leboulch and Irving London.

Between 2001 and 2005, Walter Ogier held the CEO position while the company concentrated efforts on Lentiglobin™ development for sickle cell disease and beta-thalassemia, two severe genetic conditions with high prevalence.

In September 2010, clinical trial outcomes of Lentiglobin™ were published in Nature, revealing long-term gene therapy correction for beta-thalassemia. Concurrently, the company rebranded itself as bluebird bio and appointed Nick Leschly as chief executive officer.

bluebird bio launched its initial public offering in June 2013, raising $116 million. A year later, in June 2014, it expanded its technological capabilities by acquiring Precision Genome Engineering Inc. for up to $156 million.

In November 2017, a collaboration was formed with Celgene (now Bristol-Myers Squibb) to develop bb2121, an anti-BCMA CAR-T therapy targeting multiple myeloma. Although the FDA initially issued a refusal to file in May 2020, the application was subsequently accepted later that year with a PDUFA target date set for March 2021.

August 2018 marked the beginning of a partnership with Regeneron Pharmaceuticals aimed at creating novel cancer cell therapies, supported by a $100 million investment from Regeneron.

In November 2021, bluebird bio spun off its oncology division into an independent entity named 2seventy bio, focusing exclusively on immuno-oncology cell therapy development.

Due to financial challenges, bluebird bio reduced its workforce by approximately 25-30% between 2022 and 2024. In June 2025, ownership transitioned to investment funds managed by The Carlyle Group and SK Capital Partners, which provided capital infusion to facilitate commercial growth.

Products

• Zynteglo: This therapy (betibeglogene autotemcel) received European Commission authorization in June 2019 and FDA approval in August 2022 for treating beta thalassemia, a hereditary blood disorder group. The FDA granted it orphan drug status along with breakthrough therapy designation.
• Skysona: Elivaldogene autotemcel earned European Commission approval in July 2021 for treatment of adrenoleukodystrophy.
• Lyfgenia: Approved by the FDA in December 2023 for individuals aged 12 and older suffering from sickle cell disease with prior vaso-occlusive episodes. Priced at $3.1 million wholesale, it includes a boxed warning regarding potential hematologic malignancy risks. Bluebird bio has instituted outcomes-based contracts tied to Lyfgenia that involve three years of patient follow-up; these agreements reduce payer expenses if hospitalizations related to sickle cell complications occur. Since its approval, bluebird secured two significant reimbursement deals covering roughly 200 million people across the U.S.